MedTrace Logo

TAF to Prevent HBV Reactivation in Cancer Patients

NCT04619082 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-11-12

No results posted yet for this study

Summary

Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.

Conditions

  • Hepatitis B Reactivation

Interventions

DRUG

Tenofovir alafenamide

Tenofovir alafenamide 25 mg once per day for one year

Sponsors & Collaborators

  • St. Martin De Porress Hospital

    collaborator OTHER

  • Dalin Tzu Chi General Hospital

    collaborator OTHER

  • National Taiwan University Hospital, Yun-Lin Branch

    collaborator OTHER

  • Chi Mei Medical Hospital

    collaborator OTHER

  • Chiayi Christian Hospital

    lead OTHER

Principal Investigators

  • Po-Yueh Chen, MD · Ditmanson Medical Foundation Chiayi Christian Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04619082 on ClinicalTrials.gov